GO
Loading...

Pharmaceuticals

More

  • Aug 26- Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck& Co's experimental immunotherapy pembrolizumab, in hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy. The largest U.S. drugmakers said the combination study will begin in 2015 and be conducted by Pfizer.

  • Ebola is 'contained' in Nigeria: Health minister Tuesday, 26 Aug 2014 | 12:05 PM ET
    A pharmacist searches for drugs in a pharmacy in Lagos, Nigeria, July 26, 2014.

    Nigeria's health minister has insisted the Ebola outbreak has been contained in the country.

  • Aug 26- Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck& Co's experimental immunotherapy pembrolizumab, in the hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy. The largest U.S. drugmakers said the combination study will begin in 2015 and be conducted by Pfizer.

  • Roche's blockbuster pharma deal     Monday, 25 Aug 2014 | 3:47 PM ET

    CNBC's Meg Tirrell breaks down the mega deal between Swiss pharmaceutical firm Roche and InterMune for $8.3 billion.

  • Roche CEO: InterMune perfect strategic fit     Monday, 25 Aug 2014 | 11:18 AM ET

    CNBC's Meg Tirrell speaks to Roche CEO Severin Schwan, and InterMune CEO Daniel Welch, about Roche's $8.3 billion acquisition of InterMune and the opportunity for the drug Esbriet in the U.S.

  • Surani Fernando, EMEA deputy editor at Biopharm Insight, says she was "surprised" at the value of Roche's $8.3 billion purchase of Intermune.

  • *Deal boosts Roche presence in respiratory medicine. LONDON/ ZURICH, Aug 24- Roche Holding AG has agreed to buy U.S. biotech company InterMune Inc for $8.3 billion in cash, marking the latest multibillion-dollar deal in a consolidating pharmaceutical sector.

  • Roche to buy US biotech firm InterMune for $8.3B Sunday, 24 Aug 2014 | 12:49 PM ET

    BERLIN— Swiss pharmaceutical company Roche said Sunday it has reached an $8.3 billion deal to buy InterMune Inc., a California- based developer of treatments for lung diseases. The companies have reached an agreement under which Roche will acquire InterMune in an all-cash transaction, paying $74.00 per InterMune share, Roche said.

  • British Ebola patient to be evacuated: Official Sunday, 24 Aug 2014 | 4:05 AM ET

    The first British citizen confirmed to be infected with the deadly Ebola disease is being evacuated from Sierra Leone.

  • Big change for pain drugs     Friday, 22 Aug 2014 | 2:12 PM ET

    CNBC's Meg Tirrell reports the Drug Enforcement Administration is changing the rules around pain drugs like Vicodin. The drugs will be deemed "schedule 2 substances," versus the less restrictive "schedule 3."

  • Lilly psoriasis drug fares well in late-stage test Thursday, 21 Aug 2014 | 8:55 AM ET

    INDIANAPOLIS— Drugmaker Eli Lilly and Co. said its potential psoriasis treatment fared better than both a fake drug and a competitor's product during late-stage testing on patients with the most common form of the skin disease.

  • Aug 21- Eli Lilly and Co said its experimental psoriasis drug was found to be more effective in clearing skin than a generic treatment and a placebo in late-stage studies. The most common inflammatory disease in the United States- it can occur on any part of the body- it is associated with diabetes and heart disease.

  • Hospira filed a lawsuit in U.S. District Court in Maryland on Tuesday asking for a temporary restraining order against the FDA, saying the agency's decision to allow generic Precedex went against its own rules.

  • NEW YORK/ BOSTON, Aug 20- A few months ago, an innovative partnership between Valeant Pharmaceuticals and billionaire investor William Ackman to buy Botox maker Allergan Inc looked like a blueprint for success.

  • FDA approves new drug for rare genetic disease Tuesday, 19 Aug 2014 | 6:00 PM ET

    Cerdelga is from Genzyme, the specialty drugmaker that introduced the first drug for Gaucher's disease 20 years ago. The oral treatment could serve as an alternative to Genzyme's best-selling drug Cerezyme, which is given intravenously. Genzyme says it will soon release pricing for its new drug.

  • Aug 19- Botox maker Allergan Inc has approached Salix Pharmaceuticals Ltd and at least one other company about a potential takeover in a bid to avert the $53 billion hostile takeover from Valeant Pharmaceuticals International Inc, the Wall Street Journal said. Allergan and Salix declined to comment on the matter.

  • AstraZeneca says DOJ closes probe into drug trial Tuesday, 19 Aug 2014 | 12:39 PM ET

    WASHINGTON— British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action. The London- based drugmaker said in a statement Tuesday: " AstraZeneca has always had absolute confidence in the integrity of the PLATO trial."

  • Fighting obesity with Rxs     Monday, 18 Aug 2014 | 2:17 PM ET

    Zafgen CEO Tom Hughes discusses the company's dedication to tackle obesity, with CNBC's Meg Tirrell. Hughes says the new drug works to impact the way the body handles fat.

  • Next wave of diet drugs     Monday, 18 Aug 2014 | 1:16 PM ET

    Obesity has big potential for drug makers. CNBC's Meg Tirrell examines why physicians have been cautious to adopt new diet drugs.

  • Allergan names Hindman chief financial officer Monday, 18 Aug 2014 | 1:12 PM ET

    IRVINE, Calif.— Botox maker Allergan, which is fighting a hostile takeover bid from Valeant Pharmaceuticals, has named longtime executive Jim Hindman its new chief financial officer. Allergan Chairman and CEO David E.I. Pyott said in a statement from the company that Edwards told him back in February that he was thinking about stepping down later in the year.